By Nana O 
A groundbreaking collaborative effort involving researchers from the University of Michigan, Dana Farber Cancer Institute, and the Medical University of Vienna has unveiled a promising new therapeutic avenue for high-grade glioma, a devastating and often fatal form of brain cancer affecting both children and adults. The study, published in the esteemed journal Cancer Cell, highlights the efficacy of avapritinib, a drug already FDA-approved for other conditions, in targeting a specific genetic alteration common in these aggressive tumors. This development offers a much-needed glimmer of hope in a field historically plagued by limited treatment options and a dire prognosis.
The Persistent Challenge of High-Grade Glioma
High-grade gliomas represent a formidable challenge in oncology. Their aggressive nature, propensity for recurrence, and tendency to infiltrate critical brain regions make surgical intervention difficult and often incomplete. Compounding these issues is the formidable blood-brain barrier (BBB), a highly selective physiological barrier that severely restricts the passage of most therapeutic agents into the central nervous system. For decades, treatment strategies have largely relied on surgery, radiation, and conventional chemotherapy, with limited success in achieving long-term remission, particularly for recurrent disease. The median survival for high-grade gliomas, especially pediatric forms like Diffuse Intrinsic Pontine Glioma (DIPG), often hovers around 12-18 months, underscoring the urgent need for innovative therapeutic approaches.
Unlocking a Genetic Key: The Role of PDGFRA
The collaborative research team focused on identifying specific genetic drivers within high-grade glioma cells that could be targeted by existing or novel drugs. Their investigation centered on the PDGFRA gene, a frequently mutated gene in various cancers, including a significant subset of high-grade gliomas. PDGFRA encodes a receptor tyrosine kinase, a protein that plays a crucial role in cell growth and division. Aberrant activation of this pathway due to mutations in PDGFRA can lead to uncontrolled tumor proliferation.
"We were excited to see that avapritinib essentially shut off PDGFRA signaling in mouse brain tumors," stated Dr. Carl Koschmann, M.D., ChadTough Defeat DIPG Research Professor and Clinical Scientific Director of the Chad Carr Pediatric Brain Tumor Center at C.S. Mott Children’s Hospital. Dr. Koschmann, a pivotal figure in this research, explained that outside of surgery and radiation, effective drug treatments for high-grade gliomas, especially upon recurrence, are remarkably scarce. The team’s strategic decision to target PDGFRA, a common culprit in these tumors, represented a logical and promising "inroad" to discovering new drug therapies.
Identifying Avapritinib: A Potent and Focused Inhibitor
The research involved extensive screening of commercially available drugs known to inhibit PDGFRA. This rigorous process led to the identification of avapritinib as the most potent and specific inhibitor of PDGFRA alterations among those tested. Avapritinib, marketed under the brand name Ayvakit, has already received FDA approval for treating specific types of gastrointestinal stromal tumors (GISTs) with a PDGFRA exon 18 mutation, as well as advanced, indolent, and systemic mastocytosis. This existing approval streamlined the path for exploring its potential in a new oncological context.
"We’d been doing screens with a lot of commercially available drugs that inhibit PDGFRA," Dr. Koschmann elaborated. "We found avapritinib to be the strongest and most focused inhibitor that targets PDGFRA alterations."
Overcoming the Blood-Brain Barrier: A Crucial Breakthrough
A significant hurdle in treating brain tumors is the ability of drugs to effectively cross the blood-brain barrier. This sophisticated biological defense system, composed of tightly packed endothelial cells lining the brain’s blood vessels, prevents many potentially harmful substances from entering the delicate neural tissue. The researchers were particularly encouraged when avapritinib demonstrated its capacity to penetrate this barrier.
"Along with colleagues from the labs of Mariella Filbin, M.D., Ph.D. (Dana Farber Cancer Institute) and Johannes Gojo (Medical University of Vienna) who were investigating the effectiveness of PDGFRA inhibitors, Koschmann and his team were excited to see that avapritinib crosses the blood brain barrier, a normally high hurdle for drugs," the original report noted.
Kallen Schwark, a U-M M.D./Ph.D. student and one of the study’s lead authors, emphasized the significance of this finding: "When we gave mice the drug and showed that it reached the brain, we knew we were onto something." This preclinical validation was a critical step, confirming that avapritinib could indeed reach its intended target within the brain.
A Timeline of Discovery and Early Clinical Application
The research journey for avapritinib’s application in high-grade glioma can be traced through several key phases:
- Preclinical Investigations (Ongoing): Years of laboratory work focused on understanding the genetic landscape of high-grade gliomas, identifying key oncogenic drivers like PDGFRA, and screening potential drug candidates. This phase included extensive cell line studies and animal models to assess drug efficacy and safety.
- Identification of Avapritinib: Through systematic screening, avapritinib emerged as a prime candidate due to its potent and specific inhibition of PDGFRA.
- Preclinical Validation of Blood-Brain Barrier Penetration: Studies in animal models confirmed that avapritinib could effectively cross the BBB and reach therapeutic concentrations in brain tissue.
- Expanded Access Program (Early Clinical Application): While a formal clinical trial was not yet initiated, the promising preclinical data led to the establishment of an expanded access program, allowing a select group of patients to receive avapritinib under compassionate use provisions. This program was facilitated by Blueprint Medicines, the manufacturer of avapritinib.
- First-in-Human Treatment (Eight Patients): "Across multiple international institutions, we treated the first eight patients with high-grade glioma with avapritinib," Dr. Koschmann reported. This early clinical experience provided invaluable real-world data on the drug’s tolerability and initial efficacy.
- Clinical Trial Enrollment (Phase I Pediatric Solid Tumor Trial): The positive results from both preclinical studies and the expanded access program provided a strong rationale for incorporating avapritinib into formal clinical trials. This led to its inclusion in a Phase I pediatric solid tumor trial, which has recently completed patient accrual. Analysis of the data from this trial is currently underway.
Promising Early Clinical Outcomes
The expanded access program provided the first glimpse into avapritinib’s impact on human patients with high-grade glioma. "The patients tolerated the drug well and in three of the eight patients, we were able to see their tumors shrink," Dr. Koschmann shared. This initial response rate, while from a small cohort, is highly encouraging given the aggressive nature of the disease and the limited success of existing therapies. Tumor shrinkage in three out of eight patients translates to a 37.5% objective response rate in this early cohort, a figure that significantly outperforms many established treatment paradigms for recurrent high-grade gliomas.
This preliminary clinical data, coupled with the robust preclinical findings, was instrumental in paving the way for further clinical investigation. It provided the necessary evidence to support the inclusion of pediatric high-grade glioma in a Phase I pediatric solid tumor trial. The completion of accrual for this trial marks a significant milestone, bringing researchers closer to understanding avapritinib’s potential as a standard of care.
Broader Implications and Future Directions
The success of avapritinib in crossing the blood-brain barrier and demonstrating anti-tumor activity represents a significant step forward in the fight against brain cancers. It validates the strategy of targeting specific oncogenic pathways within the brain and offers a blueprint for future drug development.
"We have very few examples of drugs entering brain tumors like this and shutting down key oncogenic pathways," Dr. Koschmann emphasized. "These results support a lot of ongoing efforts to build on the success of avapritinib and other brain penetrant small molecule inhibitors."
The implications of this research extend beyond avapritinib itself. It fuels optimism for the development of a new class of brain-penetrant small molecule inhibitors that can effectively target various genetic alterations driving brain tumors. This approach has the potential to revolutionize treatment paradigms, offering more precise and less toxic therapies compared to traditional systemic chemotherapy.
However, the researchers are cautious about overstating the immediate impact. "We know a single drug is not going to be enough for this disease," Dr. Koschmann stated pragmatically. High-grade gliomas are complex and often evolve resistance mechanisms. Therefore, the future of treatment likely lies in combination therapies.
"The way to make true progress will be combining many different types of modalities, like combining drugs that are target pathways activated by the first drug," he explained. "We already have a follow-up story on targeting avapritinib with MAP kinase inhibitors that we are just as excited about."
This forward-looking perspective highlights the ongoing commitment to developing comprehensive treatment strategies. By understanding the molecular underpinnings of tumor growth and resistance, researchers aim to develop combination regimens that can overcome these challenges and achieve more durable responses. The exploration of targeting pathways activated downstream of PDGFRA, such as the MAPK pathway, represents a logical next step in this iterative process of scientific discovery.
A Glimpse of Hope for Patients and Families
For families grappling with a high-grade glioma diagnosis, the news of promising research like this offers a much-needed beacon of hope. While avapritinib is still undergoing rigorous clinical evaluation, its demonstrated ability to shrink tumors in a subset of patients, coupled with its favorable tolerability profile, suggests it could become a vital addition to the limited arsenal of treatments available. The potential to improve survival rates and quality of life for individuals diagnosed with these devastating cancers is a powerful motivator for continued research and clinical development. The journey from laboratory discovery to widespread clinical application is often long and arduous, but the progress made with avapritinib offers a compelling testament to the power of scientific collaboration and targeted drug development in the relentless pursuit of a cure for brain cancer. The ongoing analysis of the Phase I trial data will be crucial in determining the next steps for avapritinib and its potential to transform the treatment landscape for high-grade glioma patients worldwide.
